Search form

Career Development Award


Printer Friendly and PDF

Career Development Award

Career Development Award

Letter of Intent Deadline: December 22, 2014
Application Deadline: March 16, 2015
Award Start Date: July 1, 2015

The National Hemophilia Foundation (NHF), a nonprofit organization founded in 1948, is dedicated to finding better treatments and cures for inheritable bleeding disorders and to preventing the complications of these disorders through education, advocacy, and research. NHF seeks research grant applications from established investigators, preferably at the assistant professor level or above, who have demonstrated a commitment to bleeding disorders research. We especially encourage innovative projects that promote the development of novel technologies and/or therapies to advance the field of bleeding disorders research. The funding for this award has been made possible by a generous grant from Novo Nordisk, Inc.

Eligibility Requirements

NHF/Novo Nordisk Career Development Award (CDA) candidates must hold an MD, PhD, or equivalent degree, with no more than six years of postdoctoral years of experience or greater than six years since completing their medical training. United States citizenship is not required, but applicants must be affiliated with or be faculty members of domestic organizations such as universities, colleges, hospitals or laboratories. Only non-commercial institutions and investigators associated with a non-commercial institution are eligible.

The CDA award recipient will be expected to spend at least 90% of their working time on the funded research project. The CDA recipient and his/her mentor are expected to remain at their institution for the duration of the project. Letters of support from appropriate institutional officials (department chair and financial grants officer) indicating the institution’s commitment to allow the candidate to focus his/her efforts on the stated research project will be required for the application.

Scope of Research

NHF is interested in funding innovative research studies to be carried out at the sub cellular, cellular, animal or human (patient) levels.

Studies to evaluate the genetic and immunologic bases for inhibitor development may lead to strategies to circumvent this potential complication of gene transfer. This research could provide the opportunity to determine the prognostic indicators that place patients at risk of inhibitor development. Inhibitor research may also lead to the development of synthetic replacement factor and gene therapy products with decreased immunogenicity. This includes research on genotype/phenotype relationships and susceptibility to inhibitors.

Better functional assays for clotting factor proteins are also needed. Reproducible, low-volume measure of factor VIII and factor IX activity in different animal models would greatly facilitate validation of in vivo gene therapy studies as well as innovative alternative treatment strategies. Structural studies of clotting factor proteins are needed in order to design more efficacious, longer-lived clotting factor proteins. Development of both small, biologically active, orally delivered molecules and improved protein delivery systems represent strategies that could lead to advances in our understanding of bleeding disorders.

While gene therapy has been an approach which has shown much promise, no one method has been demonstrated to be superior. Multiple experimental strategies may be undertaken to help find a “cure” for bleeding disorders. Research on the nature, propagation, and use of hematopoietic, liver, or other stem cells as an approach for gene transfer for hemophilia and other bleeding disorders may provide novel approaches for the treatment of these disorders.


All interested candidates need to submit a ‘Letter of Intent’ by no later than 5 pm EST on Monday, December 22, 2014. Letters of intent will be evaluated by members of NHF’s Research Review Committee who will collectively decide upon the candidates invited to submit a CDA application. If selected, candidates will have until March 16, 2015 to submit their full CDA application to NHF. All grant applications are subjected to a rigorous peer review process. Applications will be reviewed on scientific merit and scored in terms of significance, approach, innovation, investigator and environment.

CDA letters of intent need to be on institutional letterhead and will not be considered for review unless signed by the applicant. Letters should be no more than 2 pages in length and include a brief introduction of the candidate-researcher, his/her mentor, institution and a description of the proposed research project. Letters must also include a CV (NIH-style biosketch) for both the candidate as well as the mentor.

Letters of intent should be sent to Angelina Wang at NHF, 7 Penn Plaza, Suite 1204, New York, NY 10001. Any additional questions can be directed to